Translatable Synaptic & Lipid Biomarkers for Early Parkinson’s: Insights from Longitudinal Multi-Modal Signatures
- Identifying novel plasma lipid and synaptic protein biomarkers that change longitudinally in early Parkinson’s, enabling earlier detection and patient stratification
- Correlating these biomarkers with clinical progression and functional decline to enhance predictive power in trial endpoints
- Enabling tighter selection and more efficient monitoring in clinical trials, reducing sample sizes and improving sensitivity to detect disease-modifying effects